Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, has entered into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, moving the company closer to evaluating a potential first-in-class treatment for progressive forms of MS. For investors and the biotech industry, this milestone underscores Quantum's progress in advancing its lead compound and highlights the growing interest in novel neuroprotective therapies for MS.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business. Lucid-MS is an investigational New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. If successful, this mechanism could address a significant unmet need in MS treatment, where current therapies primarily manage symptoms rather than halt disease progression. To view the full press release, visit https://ibn.fm/CZH9U.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is dedicated to building a portfolio of innovative assets for challenging disorders. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights. This diverse pipeline reflects Quantum's strategy to leverage multiple revenue streams while pursuing high-impact therapeutics. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
The agreement with Thermo Fisher is significant because it validates Quantum's clinical strategy and provides access to top-tier research services. Thermo Fisher's PPD business is a global leader in clinical research, and its involvement could enhance trial efficiency and credibility. For the MS community, the trial represents hope for a disease-modifying therapy that targets an underlying cause rather than just symptoms. For investors, it signals a potential value catalyst as Quantum advances its lead asset through costly and time-consuming clinical phases.
BioMedWire, a specialized communications platform focused on biotechnology and life sciences, disseminated this announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. The platform also provides press release enhancement and social media distribution to maximize reach. Such broad dissemination ensures that developments like Quantum's trial progress reach a wide audience of investors and industry stakeholders, which is crucial for a clinical-stage company seeking visibility and support. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website: https://www.BioMedWire.com/Disclaimer.
